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High titers of anti-GA1 antibodies have been associated with neurological syndromes. In most cases, these antibodies cross-react with the
structurally related glycolipids GM1 and GD1b, although specific anti-GA1 antibodies have also been reported. The role of specific anti-GA1
antibodies is uncertain since the presence of GA1 in the human nervous system has not been clarified. A rabbit was immunized with GD1a and its
sera were screened for antibody reactivity by standard immunoassay methods (HPTLC-immunostaining and ELISA). Anti-GD1a antibodies were
not detected but, unexpectedly, anti-GA1 IgG-antibodies were found. Antibody binding to GA1 was inhibited by soluble GA1 but also by GD1a.
These results indicate that the rabbit produced antibodies that recognize epitopes present on the glycolipids, that are absent or not exposed on solid
phase adsorbed GD1a. We investigated the presence of these unusual anti-ganglioside antibodies in normal and neurological patient sera.
Approximately, 10% of normal human sera contained low titer of specific anti-GA1 IgG-antibodies but none of them recognized soluble GD1a.
High titers of IgG-antibodies reacting only with GA1 were detected in 12 patient sera out of 325 analyzed. Of these, 6 sera showed binding that
was inhibited by soluble GD1a and four of them also by GM1. This new type of anti-ganglioside antibodies should be considered important
elements for understanding of the pathogenesis of these diseases as well as their diagnosis.
D 2005 Elsevier B.V. All rights reserved.Keywords: Ganglioside; Anti-GD1a antibody; Anti-GM1 antibody; Anti-GA1 antibody; Neuropathy; Motor syndrome1. Introduction
High titers of anti-GA1 (asialo-GM1 ganglioside) antibodies
have been associated with a variety of motor syndromes such
as Guillain–Barre´, Multifocal Motor Neuropathy, and Motor
Neuron Disease [1–6]. In most cases they appear to be cross-
reacting antibodies that recognize the Galh(1–3)GalNAc
epitope shared by GA1, GM1 and GD1b as well as neural
glycoproteins [5]. However, high titers of specific anti-GA1
antibodies not cross-reacting with GM1 and GD1b have also
been reported [4,7,8]. The exact role of these GA1 specific
antibodies is uncertain because the presence of GA1 glycolipid
in the human nervous system has not been definitively proved.0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.11.005
* Corresponding author. Fax: +54 351 4334074.
E-mail address: gnores@dqb.fcq.unc.edu.ar (G.A. Nores).Although several authors reported traces of GA1 glycolipid in
nervous tissues [9–11], there have been no experiments ruling
out hydrolysis of GM1 as a source of GA1 during the post-
mortem or the purification procedure.
In an attempt to reproduce the experimental model of
neuropathy described by Nagai et al. [12], we immunized a
rabbit with GD1a ganglioside. The animal developed anti-GD1a
IgG antibodies with unusual reactivity: they bound soluble GD1a
but did not bind the glycolipid when adsorbed on solid phase, a
condition of standard immunoassays (HPTLC-immunostaining
and ELISA). Interestingly, these antibodies react with soluble
and adsorbed GA1. This result indicates the existence of anti-
ganglioside antibodies with structural requirements different
from those previously described. We studied the presence of
these unusual antibodies in sera of patients with neurological
disorders.1762 (2006) 357 – 361
http://www
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2.1. Human sera
Blood samples were obtained from 325 patients with neurological disorders
admitted to the Neurology Division, Ramos Mejı´a Hospital, Buenos Aires,
Argentina. They included patients with acute and chronic neuropathies with
sensory and/or motor symptoms, amyotrophic lateral sclerosis, and lower motor
neuron disease. Normal human blood was from healthy adult volunteers with
negative serology for common infectious diseases. After clot separation
(usually less than 3 h after extraction), sera were frozen at 70 -C until use.
2.2. Glycolipids
Asialo-GM1 (GA1) was prepared by acid hydrolysis of cow brain
gangliosides [13]. GM1, GD1a, and GD1b were prepared from human brain.
Folch upper phase of lipid extract [14] was purified by DEAE-chromatography
[15] and HPLC on Iatrobeads silica-gel column [16]. Special care was taken to
obtain chromatographically pure compounds, completely freed from each other.
2.3. Enzyme-linked immunosorbent assay (ELISA)
Twenty-five pmol glycolipids in 50 Al methanol were pipetted into
microtiter plate wells. After drying at 37 -C overnight, wells were blocked
with BSA-PBS (1% bovine serum albumin in phosphate buffered saline) for 1
h. Each well was added with BSA-PBSt (BSA-PBS with 0.05% Tween 20)
diluted serum (50 Al), incubated overnight, and washed with PBS. Binding was
detected following a 2 h incubation period with BSA-PBSt diluted (1/3000)
peroxidase-conjugated goat anti-human IgG (g chain specific; Sigma, St. Louis,
MO, U.S.A.). All the incubation steps were performed at 4 -C. After washing,
color was developed in a substrate solution containing 15 mM o-phenylene-
diamine and 0.015% H2O2 in 0.1 M sodium acetate buffer, pH 5.0, at room
temperature. The reaction was stopped after 30 min by addition of 100 Al 0.5 N
H2SO4, and OD was measured at 450 nm. Non-specific antibody binding (OD
value from a well not containing glycolipid) was subtracted from each
measurement. All samples were analyzed in duplicate. Titer values were
expressed as the maximal dilution able to produce an OD value higher than 0.1.
2.4. HPTLC-immunostaining
The glycolipid mixture (0.3 nmol each of GA1, GM1, GD1a, and GD1b) was
separated on HPTLC plates in the running solvent chloroform–methanol–
aqueous 0.2% CaCl2 (45:45:10), using a tank designed to obtain highly
reproducible chromatograms [17]. After air-drying, the plates were coated by
dipping for 2 min in a 0.5% solution of polyisobutylmethacrylate (Plexigum P
28, Ro¨hm and Haas, Darmstadt, Germany) in n-hexane–chloroform (9:1).
Plates were blocked with BSA-PBSt (1% bovine serum albumin in phosphate
buffered saline containing 0.05% Tween 20) for 1 h, incubated overnight with
BSA-PBSt diluted serum, and washed thoroughly with PBSt. Binding was
detected following 2 h incubation with BSA-PBSt diluted (1/1000) peroxidase-Fig. 1. Characterization of anti-ganglioside IgG-antibodies from a rabbit immunized
GA1, GM1, GD1a and GD1b (1 to 4) and a mixture of 0.3 nmol of each glycolipid (
glycolipids (0.3 nmol each) were incubated with diluted rabbit immune serum (1/
Antibody binding was assayed as described in Materials and methods. (C) Immunosconjugated anti-human or anti-rabbit IgG goat antibodies (Sigma, St. Louis,
MO, U.S.A.). All the incubation steps were performed at 4 -C. After washing,
color development was achieved in a substrate solution containing 2.8 mM 4-
chloro-1-naphtol and 0.01% H2O2 in methanol–20 mM Tris–HCl buffer, pH
7.4 (1:29). The reaction was stopped after 20 min by washing the plates with
water. For quantitative studies, spots were measured by densitometry scanning
at 590 k.
2.5. Soluble antigen binding inhibition assay (SABIA) and affinity
studies
We tested inhibition of antibody binding to solid-phase GA1 by soluble
GA1, GD1a and GM1. Note: the word ‘‘soluble’’ is used in this paper to denote a
physical state of the glycolipid distinct from solid phase adsorbed one;
glycolipid–detergent mixtures actually form micellar dispersion and not real
solutions. Appropriated dilutions of rabbit or human sera were preincubated
with antigen at various concentrations (from 1011 to 104 M). After 1 h, the
aliquots were assayed for antibody binding by HPTLC immunostaining.
Antibody affinity for soluble GA1, GD1a or GM1 was estimated as the
glycolipid concentration that produced 50% of the maximal inhibition of
antibody binding to GA1 (IC50). IC50 values were calculated from the slope of
the straight line in a plot of 1/inhibition vs. 1/concentration.
3. Results
A rabbit was immunized with GD1a in CFA and its serum
screened for the presence of IgG-antibody binding to GD1a and
related glycolipids. Although HPTLC-immunostaining analysis
showed no reactivity with the immunizing ganglioside (Fig.
1B), a remarkable result was obtained: the rabbit developed
antibodies that bind to GA1 (GD1a lacking both sialic acids).
Positive staining of GD1a was obtained when the HPTLC plate
was incubated with serum from a motor neuropathy patient
containing anti-GD1a antibodies (Fig. 1C), indicating that in
this condition GD1a can be recognized by antibodies. These
antibodies are not present in preimmune sera or in rabbits
injected with CFA alone (results not shown, Lopez et al. [18]).
The antibodies were further characterized by soluble antigen
binding inhibition assay (SABIA). Rabbit serum was preincu-
bated with GA1 or GD1a prior to HPTLC-immunostaining
assay. Soluble GA1 completely inhibited the anti-GA1 reactiv-
ity (Fig. 1B) but, unexpectedly, the antibody binding was also
inhibited by GD1a. The glycolipids used in the assays were
prepared in our laboratory and are completely free of GA1 (Fig.
1A) ruling out the possibility that inhibition is produced by a
GA1 contamination of the ganglioside preparations.with GD1a. (A) Orcinol staining of glycolipids used in this studied: two nmol of
5) were chromatographed on HPTLC plates. (B) Plates containing a mixture of
50) that was previously incubated with PBS or with GA1 or GD1a (0.1 mM).
taining of GD1a by using a patient serum containing anti-GD1a IgG antibodies.
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anti-ganglioside antibodies with unusual requirement for
binding to GD1a. These antibodies are not detected by standard
immunoassays when GD1a is used as antigen, but can be
measured by binding inhibition to GA1. We searched for this
type of antibodies in patients with neurological disorders and
normal controls.
As we reported previously [19], plasma of ¨10% of normal
humans contains weak anti-GA1 IgG–antibody reactivity. In
HPTLC-immunostaining, this binding is detected at low
dilution (usually 1/5) and is not inhibited by preincubation
with GD1a (Fig. 2). 325 neurological patients and 22 disease
controls were screened for high anti-GA1 IgG reactivity
(detected at 1/20 dilution or higher) and no reactivity with
GD1a, GM1, GM3, GM2, GD3, GD1b, GT1b, GQ1b and LM1.
Twelve neurological patients met this criteria and of them, 6
showed partial or total binding inhibition by soluble GD1a (Fig.
2, Table 1). Inhibition with GM1 was also observed in 4 of
these 6 patients (Table 1) with not additive effect, indicating
that both glycolipids are recognized by the same antibodies.
ELISA determination of IgG antibody from positive patient
sera showed reactivity against GA1 (titer values founded were:
1/40; 1/160; 1/40; 1/20; 1/160 and 1/80 for patient 202; 209;
261; 262; 420 and 512 respectively) but not to GD1a.
The affinity of the antibodies for GA1, GD1a and GM1 was
estimated by quantitative SABIA, considering the concentra-
tion of soluble antigen necessary to produce 50% of maximal
inhibition (IC50) as a relative value of antibody affinity. IC50
values measured for patient and control sera are summarized in
Table 1. In terms of affinity for GD1a, patients can be classified
in two groups. The first group (low affinity) included patients
with IC50 values equal or higher than 10
7 M, while in the
second group (high affinity antibodies) the values ranged from
108 to 1010 M. In the first group the IC50 values for GA1 are
similar or lower than those for GD1a, whereas they are higher in
the second group.
Clinical features of each patient are shown in Table 1. These
unusual anti-ganglioside antibodies are most abundant among
patients characterized by motor deficits and exclusively if only
high affinity antibodies are considered. This observation isFig. 2. Characterization of anti-GA1 IgG antibodies in patients and normal human s
0.1 mM GD1a. Two representative patient sera having anti-GA1 antibodies with co
human serum.consistent with previous associations described for ‘‘classical’’
anti-GD1a or anti- GM1 antibodies [1,6,20–22].
4. Discussion
The standard methods to study anti-glycolipid antibody
binding (HPTLC-immunostaining and ELISA) involve fixing
the glycolipid on solid phase surface through its hydrophobic
moiety. The oligosaccharide moiety is thus exposed to the
medium, simulating the natural condition on the cell mem-
brane. Antibodies reacting with glycolipids in standard
methods usually also give positive reaction in cell or tissue
staining, liposomes, and affinity columns. In this study, we
demonstrated the presence of a new type of anti-ganglioside
antibodies with behavior different from that of the ‘‘classical’’
antibodies—they bind soluble GD1a and in some instances also
GM1, but not GD1a nor GM1 adsorbed on solid phase. Using
standard methods we were able to detect these antibodies
because they react with GA1, the asialo form of complex
gangliosides. The presence of anti-ganglioside antibodies with
unusual binding behavior is not a surprising fact because they
have been described in neurological patients [23–25].
We first detected these antibodies in a rabbit immunized
with GD1a, but later found them also in 6 out of 325
neurological patients. They were found mainly in patients with
motor deficits, in agreement with previous reports of ‘‘classi-
cal’’ anti-GD1a or anti-GM1 antibodies in Guillain–Barre´
syndrome, multifocal motor neuropathy, and lower motor
neuron disease [1,6,20–22].
A question emerges from our results: why do these antibodies
recognize GA1 and not GD1a or GM1 in standard immunoassays,
while they recognize soluble form of these glycolipids? The
answer to this question appears easy to explain but difficult to
demonstrate: the antibodies recognize epitopes present on both
molecules that are not exposed on fixed GD1a or GM1 but can be
accessed when both glycolipids have less movement restriction
(soluble form).
Analysis of the tridimensional structures of these glycolipids
supports the role of epitope exposure on antibody binding.
Spatial disposition of monosaccharides in the GA1, GM1, andera. Sera dilutions of a normal (1/5) and patients (1/20) were preincubated with
mplete or partial binding inhibition by soluble GD1a are shown. NHS: normal
Table 1
Estimation of antibody affinity for soluble GA1 and GD1a glycolipids
Patient Diagnosis Maximal inhibition
by GM1/GD1a (%)
IC50
GA1 GD1a GM1
NHS – – 2.0105 M NR NR
202 MF 47 4.2108 M 1.6106 M >1.0105 M
209 AN 88 3.9106 M 1.6106 M NR
261 LMND 35 ND >1.0105 M NR
262 ALS 66 ND 1.6108 M 8.8108 M
420 MN 100 4.5108 M 3.51010 M 4.71010 M
512 MN 34 3.2106 M 2.61010 M >1.0105 M
Antibody affinity was estimated by quantitative SABIA, considering the concentration of soluble antigen necessary to produce 50% of maximal inhibition (IC50) as a
relative value of antibody affinity. IC50 values were calculated from the slope of the straight line in a plot of 1/inhibition vs. 1/concentration. Sera having IC50 values
lower than 108 M are considered that contain high affinity antibodies. NR, not reactive (not inhibited by 104 M GD1a or GM1); ND, not determined; NHS, normal
human serum; MN, motor neuropathy; LMND, lower motor neuron disease; AN, ataxic neuropathy; MF, Miller Fisher syndrome.
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NMR and minimum energy calculation [26–29]. Fig. 3 shows
pictures of CPK models of GA1, GM1 and GD1a oligosaccha-
ride, made using the torsion angles described by Sabesan et al.
[27]. The four sugars forming GA1 and the neutral backbone of
GD1a and GM1 adopt a belt shape with two clear faces: a
hydrophobic face characterized by high density of CUH
groups, and a hydrophilic face with a high density of hydroxyl
groups. In GD1a and GM1 the NeuNAc residues are attached to
the Gal residues in such a way that they cover part of the
hydrophobic face. Assuming that antibodies reacting with GA1,
GM1 and GD1a should bind to shared epitopes, the epitopes
should be on the hydrophilic face, because binding to those
present on the hydrophobic face is sterically impeded by the
NeuNAc residues in the GD1a molecule. It is widely accepted
that when glycolipids are fixed through the ceramide and
viewed laterally, the oligosaccharide molecules resembles
flower corollas attach to a ceramide stalk (Fig. 3). The
GlcUGal bond is flexible [26], allowing some freedom of
movement of the oligosaccharide chain. On the other hand, the
presence of hydrogen bond between the GalNAc acetamide
NH and the carboxyl group of the first NeuNAc produce a
structural stabilization of the oligosaccharide with restriction inFig. 3. Lateral view of CPK models of GA1, GM1 and GD1a oligosaccharides, and
using the torsion angles described by Sabesan et al. [27].the movement [26]. The first NeuNAc, GalNAc, Gal and the
second NeuNAc form a relative flat ‘‘end face’’ that is exposed
and accessible to antibodies. Classical anti-GD1a antibodies
would recognize epitopes on this ‘‘end face’’, as it was
proposed for anti-GM1 antibodies [30]. In contrast, the
antibodies described here would recognize epitopes on the
opposite face of GD1a/GM1 (the hydrophilic face) that is hidden
or not exposed. Because of the higher mobility of the GA1
oligosaccharide, the hydrophilic face would be more easily
exposed and consequently accessible to antibodies. When GD1a
and GM1 are in solution, they do not have movement
restrictions and in this ways the hydrophilic face should be
exposed in both molecules.
As shown in Table 1, different patients have different
populations of antibodies defined by affinity and cross-
reactivity. The different reactivity of the populations can be
explained on the basis of their binding to different areas on the
hydrophilic face. Similar affinity for two glycolipids indicates a
similar area present on both molecules. Differential reactivity
for GD1a/GM1 should involve the NeuNAc residues, with
higher or lower affinity depending on whether they are
included in the binding site or if they produce steric hindrance
(Fig. 3).the proposed area involved in binding of antibodies. Models were constructed
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